FDA Accepts IND Application for BIVV003, a Gene Therapy for Sickle Cell Disease – Rare Disease Report
Rare Disease Report |
FDA Accepts IND Application for BIVV003, a Gene Therapy for Sickle Cell Disease
Rare Disease Report This morning, Bioverativ Inc, announced that the US Food and Drug Administration (FDA) has accepted the company's Investigational New Drug (IND) application for BIVV003, a gene-edited cell therapy candidate for the treatment of people with sickle cell … FDA Accepts IND for Gene-Edited Cell Therapy BIVV003 for Treatment of Sickle Cell Disease |
